Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F

THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN

(2020) Keith T Flaherty et al.   JNCI-Journal of the National Cancer Institute

The SWI/SNF complex in cancer — biology, biomarkers and therapy

(2020) Priya Mittal et al.   Nature Reviews Clinical Oncology

PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective

(2020) Mingzhen Zhang et al.   CANCER RESEARCH

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

(2020) Keith T. Flaherty et al.   JOURNAL OF CLINICAL ONCOLOGY

Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.

(2020) Javier Pascual et al.   Cancer Discovery

Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma

(2019) Marcel Trautmann et al.   MOLECULAR CANCER THERAPEUTICS

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma

(2019) Yu-Fa Su et al.   CLINICA CHIMICA ACTA

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors

(2019) Franck Morschhauser et al.   MOLECULAR CANCER THERAPEUTICS

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

(2019) Neil Vasan et al.   SCIENCE

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

(2018) Jose Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

The landscape of genetic alterations in ameloblastomas relates to clinical features

(2018) Sibel Elif Gültekin et al.   VIRCHOWS ARCHIV

Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.

(2018) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

(2017) Martin Dreyling et al.   JOURNAL OF CLINICAL ONCOLOGY

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial

(2017) Chih-Jian Lih et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

(2016) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Managing Liposarcomas: Cutting Through the Fat

(2016) Gulam A. Manji et al.   Journal of Oncology Practice

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

(2015) Benjamin G Bitler et al.   NATURE MEDICINE

Coexistent ARID1A–PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling

(2015) Ronald L. Chandler et al.   Nature Communications

Activating FGFR2-RAS-BRAF Mutations in Ameloblastoma

(2014) N. A. Brown et al.   CLINICAL CANCER RESEARCH

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

(2014) Dejan Juric et al.   NATURE

Identification of recurrent SMO and BRAF mutations in ameloblastomas

(2014) Robert T Sweeney et al.   NATURE GENETICS

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

(2014) Filip Janku et al.   Cell Reports

High frequency of BRAFV600E mutations in ameloblastoma

(2013) Kari J Kurppa et al.   JOURNAL OF PATHOLOGY

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

(2013) Ningshu Liu et al.   MOLECULAR CANCER THERAPEUTICS

Mediating Resistance in Oncogene-Driven Cancers

(2013) Rafael Rosell   NEW ENGLAND JOURNAL OF MEDICINE

ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?

(2012) Jennifer N. Wu et al.   Cancer Discovery

Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma

(2011) Elizabeth G Demicco et al.   MODERN PATHOLOGY

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas

(2010) Kimberly C. Wiegand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional differences between two classes of oncogenic mutation in the PIK3CA gene

(2009) Claire Chaussade et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PIK3IP1, a Negative Regulator of PI3K, Suppresses the Development of Hepatocellular Carcinoma

(2008) X. He et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE